Posters

Identification and Biophysical Assessment of mAb AM E3, an Innovative α-TLSPR ADC Candidate Aimed at Treating TLSPR/CRLF2-Rearranged Ph-like B-ALL

IRBM poster 25013, preview
Full poster sent as PDF

About this poster

This poster presents the development and characterization of AM E3-SG3249, a first-in-class antibody-drug conjugate targeting CRLF2 for the treatment of CRLF2-rearranged Ph-like B-ALL. It highlights the biophysical properties of the ADC and evaluates its efficacy and tolerability in relevant xenograft models.

Get the full poster

Free PDF, sent to your work email.

CRLF2-Targeted ADC poster, code 25013

Please insert a company or institutional email address to receive your downloadable resource.
Privacy Policy

Related posters

Browse all IRBM posters

July 2025, code 25016Generation and Biophysical Characterization of New α-Nsp13 Helicase mAbs, as a Powerful Tool for Studying SARS-CoV-2 Replication and Therapeutic TargetingEBSA 2025April 2025, code 25011AM E3-SG3249, a First-in-Class α-CRLF2 Antibody-Drug Conjugate for the Treatment of CRLF2-Rearranged Ph-like B-ALLAACR 2025September 2024, code 24009SPR Technology for the Identification of New Therapeutic Agents from Phage Display LibrariesDIPIA

Discuss your program with the team behind this work

Explore our capabilitiesContact our scientists
Back To Top
No results found...